Status:
TERMINATED
Atomoxetine in Patients With Tourette's Syndrome
Lead Sponsor:
Poitiers University Hospital
Conditions:
Tourette Syndrome
Eligibility:
All Genders
10-35 years
Phase:
PHASE2
Brief Summary
The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.
Detailed Description
High impulsivity characterizes severe forms of Tourette's syndrome, in which motor and vocal tics are associated with various neuropsychiatric disorders as compulsive disorders, difficult to manage an...
Eligibility Criteria
Inclusion
- High impulsive patients, aged 10-35 years old, diagnosed for Tourette's syndrome as defined by the DSM-IV, never treated by Atomoxetine
- The use of effective contraception or abstinence for subjects of reproductive age
- Written informed consent
Exclusion
- Patients with mental retardation, psychotic disorders as schizophrenia, autism spectrum disorders, chronic tics which do not respond to Tourette's syndrome criteria.
- Actual severe depression
- Allergy to one of the constituents
- Severe cardiovascular or cerebrovascular diseases, Pheochromocytoma, uncontrolled hyperthyroidism, closed angle glaucoma
- IMAO treatment discontinued less than 2 months or contra-indicated associated treatment
Key Trial Info
Start Date :
May 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 19 2024
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04354103
Start Date
May 31 2022
End Date
January 19 2024
Last Update
January 23 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices civils de Lyon
Lyon, France
2
AP-HP La Pitié Salpêtrière
Paris, France
3
CHU Poitiers
Poitiers, France